| 3.25 -0.3 (-8.45%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.93 | 1-year : | 11.2 |
| Resists | First : | 5.94 | Second : | 9.59 |
| Pivot price | 1.21 |
|||
| Supports | First : | 0.03 | Second : | 0.03 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 1.24 |
| MA(100) : | 57.55 |
MA(250) : | 3386.02 |
|
| MACD | MACD : | -0.6 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 82 |
D(3) : | 68.1 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 83760 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SXTC ] has closed below upper band by 19.4%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.24 - 3.26 | 3.26 - 3.28 |
| Low: | 3.06 - 3.08 | 3.08 - 3.1 |
| Close: | 3.17 - 3.2 | 3.2 - 3.23 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Sat, 31 Oct 2026
China SXT Pharmaceuticals (SXTC) Stock Forecast & Analyst Ratings - Moomoo
Thu, 22 Oct 2026
China SXT Pharmaceuticals, Inc. (SXTC) Enacts 1-for-100 Reverse Split - TradingView
Thu, 22 Oct 2026
China SXT Pharmaceuticals, Inc. Announces Share Consolidation - TradingView
Wed, 21 Oct 2026
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right - Yahoo Finance
Sat, 10 Oct 2026
China SXT Pharmaceuticals Raises $12 Million in October Registered Direct Offering - The Globe and Mail
Fri, 09 Oct 2026
China SXT raises $12M in registered direct offering - Dealroom
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | -5 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 103570 (%) |
| Held by Institutions | 401680 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -153.3 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | -44 % |
| Gross Profit (p.s.) | 133710 |
| Sales Per Share | 612903 |
| EBITDA (p.s.) | -3.79032e+006 |
| Qtrly Earnings Growth | 40 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.584e+006 |
| Dividend | 656 |
| Forward Dividend | 186 |
| Dividend Yield | 20500% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|